LPL Financial LLC decreased its position in shares of Schrödinger, Inc. (NASDAQ:SDGR – Free Report) by 5.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,951 shares of the company’s stock after selling 1,073 shares during the period. LPL Financial LLC’s holdings in Schrödinger were worth $996,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SDGR. Arete Wealth Advisors LLC bought a new stake in Schrödinger during the first quarter worth approximately $25,000. Nisa Investment Advisors LLC raised its holdings in Schrödinger by 5,900.0% during the first quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock worth $32,000 after purchasing an additional 1,180 shares in the last quarter. Strs Ohio bought a new stake in Schrödinger during the second quarter worth approximately $49,000. Money Concepts Capital Corp bought a new stake in Schrödinger during the fourth quarter worth approximately $60,000. Finally, US Bancorp DE raised its holdings in Schrödinger by 69.2% during the first quarter. US Bancorp DE now owns 1,932 shares of the company’s stock worth $66,000 after purchasing an additional 790 shares in the last quarter. Institutional investors own 81.14% of the company’s stock.
Schrödinger Stock Down 0.1 %
Schrödinger stock opened at $30.86 on Friday. The company’s fifty day simple moving average is $27.19 and its 200-day simple moving average is $35.67. Schrödinger, Inc. has a 12 month low of $15.85 and a 12 month high of $59.24. The stock has a market cap of $2.22 billion, a P/E ratio of 55.11, a P/E/G ratio of 28.68 and a beta of 1.41.
Wall Street Analysts Forecast Growth
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
- Five stocks we like better than Schrödinger
- Investing in the Best Airline Stocks
- 3 large caps with red hot RSIs with upside
- Find and Profitably Trade Stocks at 52-Week Lows
- Johnson Controls International: Nothing but upside for investors
- Best Stocks Under $10.00
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Schrödinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrödinger and related companies with MarketBeat.com's FREE daily email newsletter.